Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive.

Published byAlban Blair Modified over 8 years ago

Similar presentations

Presentation on theme: "Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive."— Presentation transcript:

1 Supplementary Figure 1

2 Supplementary Figure 2

3 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive 29 50 Negative 29 50 HER2 Positive 7 12 Negative 51 88 Status Stable 18 31 Progression 40 69 Supplementary Table 1: Classification of patients based on receptor and disease status

4 AssayBlood volume per testCTC enrichment principleDetection method CellSearch Method7.5 mLImmunomagnetic using EpCAM Visual confirmation of CK + /DAPI +/ CD45 - cells using automated fluorescence imaging CSV Method 7.5 mL (for comparative analysis) Depletion of CD45 + cells and positive selection of cell-surface vimentin positive cancer cells using 84-1 antibody Visual confirmation of CSV + /Cancer specific marker using Confocal Imaging Supplementary Table 2 Comparison between two detection techniques Abbreviations: CSV= Cell-surface vimentin, CK= Cytokeratin,

5 K coefficientDegree of AgreementAgreement (%) Comparison of Progressive population with the CellSearch CTC test -0.017Poor45% Comparison of Stable population with the CellSearch CTC test 0.440Moderate66.67% Supplementary Table 3 Concordances between CSV and CellSearch detection techniques Abbreviations: CSV= Cell-surface vimentin, CTC= Circulating tumor cells.

6 Triple NegativeLuminal ALuminal BHER2 Type CTCs<5 StableProgressionStableProgressionStableProgressionStableProgression CSV < 5441022010 CellSearch < 52810122110 CTCs≥ 5 CSV ≥ 5081220301 CellSearch ≥ 5241120101 CSV: Cell-surface vimentin; CTCs: Circulating tumor cells; ER: Estrogen receptor; PR: Progesterone receptor ; HER2: HER2/neu receptor; Triple negative: ER - PR - HER2 - ; Luminal A: ER/PR + HER2 - Luminal B: ER/PR + HER2 +, HER2 Type: ER/PR - HER2 + Supplementary Table 4: Receptor based classification for individual samples with stable/progression status as determined by both techniques

7 Triple Negative (n=16) SensitivitySpecificity Positive Predictive Value Negative Predictive Value CSV66.67%100% 50% CellSearch33.34%50%66.67%20% Summation (T h 5)83.33%25%76.92%33.33% Summation (T h 8)83.33%75%90.91%60% Luminal A (n=35) CSV91.67%90.91%95.65%83.33% CellSearch50%90.91%92.3%45.45% Summation (T h 5)95.83%72.73%88.46%88.89% Summation (T h 8)95.83%81.82%92%90% Supplementary Table 5: Analysis of Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value based on receptor status of patients CSV: Cell-surface vimentin Summation: sum of CTC counts from 84-1 and CellSearch methods. Triple negative: ER - PR - HER2 - ; Luminal A: ER/PR + HER2 - T h 5 indicates a threshold of 5 CTCs/ 7.5 mL as cutoff. T h 8 indicates a threshold of 8 CTCs/ 7.5 mL as cutoff.

8 n=20ProgressionStable Nuclear EpCAM131 No Nuclear EpCAM24 Supplementary Table 6: Analysis of Nuclear EpCAM Status

9 SensitivitySpecificityPositive Predictive ValueNegative Predictive Value n=2086.67%80%92.86%66.67% Supplementary Table 7: Sensitivity, Specificity, Positive prediction and Negative prediction values for Nuclear EpCAM method

10 SampleAgeER/PR/HER2 statusTreatmentDisease status84-1CellSearch S165ER+/PR-/HER2+TaxolProgression201 S342ER+/PR+/HER2-letrozoleStable00 S448ER+/PR+/HER2+trastuzumabStable00 S561ER+/PR+/HER2-paclitaxelStable10 S778ER+/PR+/HER2-everolimus, exemestane and zoledronic acidProgression12 S953ER+/PR+/HER2+Ixabepilone plus capecitabine, zoladex + AIProgression3274 S1044ER-/PR-/HER2+docetaxel, pertuzumab and trastuzumabProgression1244 S1127ER-/PR-/HER2-Abraxane and bevacizumabProgression222 S1272ER+/PR+/HER2-tamoxifenProgression010 S1358ER+/PR+/HER2-TaxolProgression569 S1467ER+/PR+/HER2-letrozoleStable00 S1561ER-/PR-/HER2-Taxol and AvastinStable21 S1649ER+/PR+/HER2-Afinitor and tamoxifenProgression754 S1746ER-/PR-/HER2-eribulinProgression734 S1837ER-/PR-/HER2-TaxolStable14 S1969ER+/PR-/HER2-everolimus, exemestane and zoledronic acidStable21 S2064ER+/PR+/HER2-TaxolStable01 S2231ER+/PR+/HER2+TaxolStable34 S2353ER+/PR-/HER2-capecitabineProgression613 S2466ER+/PR+/HER2-docetaxel and zoledronicProgression811 S2658ER-/PR-/HER2-eribulinProgression13 S2748ER-/PR-/HER2-gemcitabine and carboplatinProgression171 S2836ER+/PR+/HER2-Gemzar, carboplatinProgression241 S2947ER-/PR-/HER2-MK-2206Stable411 S3052ER+/PR+/HER2-tamoxifenStable41 S3140ER-/PR-/HER2-Taxol and AvastinProgression481 S3342ER+/PR-/HER2-abraxane plus bevacizumabProgression634 S3567ER+/PR+/HER2-everolimusProgression81 S3668ER+/PR+/HER2-everolimus, exemestane and zoledronic acidStable09 S3851ER+/PR+/HER2-Avastin and eribulinProgression133 S3965ER-/PR-/HER2-Taxol and AvastinStable05 S4060ER+/PR-/HER2-everolimus, exemestane and zoledronic acidProgression151 S4157ER-/PR-/HER2-GemzarProgression2374 S4262ER+/PR-/HER2-vinorelbineProgression167 S4354ER+/PR-/HER2+TamoxifenProgression66221 S4441ER+/PR+/HER2-AbraxaneProgression63 S4556ER-/PR-/HER2+Pertuzumab, trastuzumab, docetaxelStable11 S4635ER-/PR-/HER2-erlotinib plus pralatrexateProgression601 S4769ER+/PR-/HER2-everolimus and exemestaneProgression3010 S4966ER-/PR-/HER2-cisplatin and etoposideProgression155 S5067ER+/PR+/HER2-ArimidexStable00 S5267ER+/PR+/HER2-letrozoleStable90 S5365ER+/PR-/HER2-anastrozoleProgression72 S5452ER+/PR+/HER2-everolimus and exemestaneStable00 S5563ER-/PR-/HER2-capecitabineProgression20 S5647ER-/PR-/HER2-Avastin and eribulinProgression148369 S5759ER+/PR+/HER2-Taxol and AvastinProgression243 S5866ER-/PR-/HER2-AbraxaneProgression962 S5941ER+/PR+/HER2-eribulinProgression62 S6059ER+/PR+/HER2-Avastin and eribulinProgression660 S6192ER+/PR+/HER2-fluoxymesteroneProgression280 S6245ER+/PR+/HER2-gemcitabineProgression14226 S6376ER+/PR-/HER2-fulvestrantStable00 S6459ER+/PR+/HER2-anastrozoleProgression621 S6567ER+/PR+/HER2-everolimus and exemestaneProgression1800 S6630ER-/PR-/HER2-T-FACProgression120 S6758ER+/PR-/HER2-Abraxane and AvastinProgression30124 S6840ER+/PR+/HER2-exemestane, everolimus, and denosumabProgression1442 Supplementary Table 8: Clinical parameters, disease status and CTC counts from patients

Download ppt "Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive."

Similar presentations

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Triple-Negative Breast Cancer

Triple-Negative Breast Cancer
Tumor CompartmentStromal Compartment mask C D EF A B Supplemental Fig 1. Epithelial and stromal PD-L1 expression. AQUA scores for PD-L1 in the epithelium.

Tumor CompartmentStromal Compartment mask C D EF A B Supplemental Fig 1. Epithelial and stromal PD-L1 expression. AQUA scores for PD-L1 in the epithelium.
Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.
“Learning curve” group= 10 pts with mBrCa (ER+ or ER-) who are beginning a new therapy ~5 pts with ≥5CTC/7.5 ml Group 1 5 CTC evaluable pts* with ER+ mBrCa.

“Learning curve” group= 10 pts with mBrCa (ER+ or ER-) who are beginning a new therapy ~5 pts with ≥5CTC/7.5 ml Group 1 5 CTC evaluable pts* with ER+ mBrCa.
Circulating Tumor Cells

Circulating Tumor Cells
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Pathology Journal Reading

Pathology Journal Reading
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Circulating Tumor Cells Minetta C. Liu, MD Associate Professor of Medicine and Oncology Director, Translational Breast Cancer Research Lombardi Comprehensive.

Circulating Tumor Cells Minetta C. Liu, MD Associate Professor of Medicine and Oncology Director, Translational Breast Cancer Research Lombardi Comprehensive.
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,

Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.

Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Clinical Utility of CellSearch Richard A. Bender,MD,FACP Medical Director-Hematology/Oncology Quest Diagnostics Nichols Institute.

Clinical Utility of CellSearch Richard A. Bender,MD,FACP Medical Director-Hematology/Oncology Quest Diagnostics Nichols Institute.
Isolation of Rare Circulating Tumor Cells in Cancer Patients by Microchip Technology Toner, et al. 2007 Stephanie Bachar Matt Luchette.

Isolation of Rare Circulating Tumor Cells in Cancer Patients by Microchip Technology Toner, et al Stephanie Bachar Matt Luchette.
Isolation of Rare Circulating Tumor Cells Sunitha Nagrath et al. Presentation.

Isolation of Rare Circulating Tumor Cells Sunitha Nagrath et al. Presentation.
Isolation of rare circulating tumor cells in cancer patients by microchip technology Nagrath & Sequist et al. (2007) Journal Presentation Brigitte Morales.

Isolation of rare circulating tumor cells in cancer patients by microchip technology Nagrath & Sequist et al. (2007) Journal Presentation Brigitte Morales.
Circulating tumor cells (CTCs) in blood of breast cancer patients: Cytological detection and technical characterization Enrica Bresaola, Mara Jo Miller,

Circulating tumor cells (CTCs) in blood of breast cancer patients: Cytological detection and technical characterization Enrica Bresaola, Mara Jo Miller,
Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.
Tiffany M. Marshall Saint Mary-of-the-Woods College Mentors : Tim McKnight Measurement Science and Systems.

Tiffany M. Marshall Saint Mary-of-the-Woods College Mentors : Tim McKnight Measurement Science and Systems.

Similar presentations

Ads by Google